The European Medicines Agency (EMA) has published Revision 3 of the Guideline on Stability Testing for Applications for Variations to a Marketing Authorization, introducing updated regulatory expectations for stability data supporting post-approval changes. Effective from 15 January 2026, this revision replaces the previous version and represents an important step in strengthening lifecycle management of medicinal products across the EU. The guideline clarifies when stability data are required, the extent of testing expected, and how data should be generated and assessed to ensure that approved variations do not compromise product quality, safety, or efficacy.
The guideline applies to chemical active substances and finished products, as well as herbal substances, preparations, and herbal medicinal products. Biologicals, immunologicals, biotechnology-derived products, and radiopharmaceuticals remain outside its scope. It is designed to be used alongside existing EMA and ICH stability guidelines and the EU Variations Regulation, reinforcing a harmonized regulatory framework for post-approval changes.
A central principle of the guideline is a risk-based and science-driven approach. Applicants are expected to assess whether a proposed variation may impact the stability profile of the active substance or finished product, taking into account prior knowledge, stress testing data, and existing long-term and accelerated stability results. Comparative stability studies before and after the change are a key requirement to demonstrate that the variation does not negatively affect stability or compliance with approved specifications. The guideline also allows flexibility through scientifically justified alternatives, including Quality by Design approaches, bracketing, matrixing, and data extrapolation where appropriate.
For Type I variations (IA and IB), stability requirements follow the EU Variation Classification Guideline. While Type IA variations generally require minimal data, Type IB variations may require stability data depending on their potential impact, with requirements assessed on a case-by-case basis. When stability studies are needed, follow-up testing on commitment batches is mandatory to confirm long-term product performance.
For Type II variations, which are considered major changes with potential impact on quality, safety, or efficacy, stability data must be submitted at the time of application. The guideline provides detailed expectations for common scenarios, including changes to manufacturing sites or processes, formulation or excipient changes, modifications to batch size, introduction of non-standard sterilization methods, and changes to immediate packaging or pack configuration, particularly for sterile products. In most cases, EMA expects six months of comparative stability data generated under long-term and accelerated ICH conditions, using two to three batches, with at least pilot-scale batches. More extensive data are required for unstable active substances or critical dosage forms such as modified-release products and injectables.
The guideline also reinforces the importance of commitment batches and ongoing lifecycle oversight. For Type II variations, at least the first production-scale batch manufactured according to the approved change must be placed on long-term stability testing for the full shelf life. Marketing Authorization Holders are required to promptly notify authorities if any stability concerns arise during storage, including out-of-specification results or negative trends.
Overall, this revised guideline underscores EMA’s expectation that stability considerations are integrated early into variation planning. By adopting a proactive, risk-based stability strategy aligned with the new requirements, pharmaceutical companies can facilitate smoother variation approvals, maintain regulatory compliance, and ensure continued patient access to high-quality medicines.
Learn more: Stability testing for applications for variations to marketing authorisation - Scientific guideline
